Retinal Vascular Biomarkers in Neurodegenerative Disorders

Abstract

Retinal vascular biomarkers have emerged as a promising, non-invasive window into cerebral microvascular pathology, offering valuable insights in the context of neurodegenerative disorders. Recent advances in retinal imaging technology have facilitated the identification and quantification of subtle vascular changes that correlate with disease onset, progression, and prognosis. This review synthesizes current evidence on the epidemiology, pathophysiological mechanisms, risk factors, clinical features, diagnostic strategies, and management implications of retinal vascular biomarkers in neurodegenerative diseases, with a focus on Alzheimer’s disease, Parkinson’s disease, and related dementias. The article further discusses novel imaging modalities, emerging therapies, recent guideline recommendations, and the potential for these biomarkers to transform clinical practice and research paradigms in neurology and ophthalmology.

Introduction

Neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and vascular dementias, represent a growing global health challenge due to aging populations and increasing disease prevalence. Early diagnosis remains a significant hurdle, as neurodegeneration often precedes clinical symptoms by years. Retinal vascular biomarkers, accessible through non-invasive imaging, provide unique opportunities for detecting central nervous system (CNS) microvascular pathology. Given the embryological and anatomical continuity between the retina and brain, retinal microvasculature can reflect cerebral vascular health and neurodegenerative processes. Advances in retinal imaging including optical coherence tomography angiography (OCTA) and fundus photography have enabled detailed assessment of retinal vascular parameters, such as vessel caliber, tortuosity, and capillary density, revealing associations with neurodegenerative disease phenotypes and progression.

Epidemiology / Disease Burden

Neurodegenerative disorders account for a substantial burden of morbidity, mortality, and economic cost worldwide. Alzheimer’s disease alone affects over 50 million individuals globally, with prevalence expected to triple by 2050. Vascular contributions to cognitive impairment are increasingly recognized, and mixed pathologies are common. Epidemiological studies have demonstrated that retinal vascular abnormalities including arteriolar narrowing, venular dilation, and microaneurysms are more prevalent in patients with dementia and mild cognitive impairment compared to cognitively healthy controls. The population-based Rotterdam Study and Singapore Epidemiology of Eye Diseases Study have linked retinal microvascular signs to increased risk of incident dementia, stroke, and cognitive decline, underscoring the utility of retinal biomarkers for risk stratification in clinical and research settings.

Pathophysiology

The retina and brain share similar microvascular networks, blood–retina and blood–brain barriers, and neurovascular unit components. Neurodegenerative disorders are characterized by microvascular dysfunction, chronic hypoperfusion, blood–brain barrier breakdown, and neuroinflammation. In AD, amyloid-β deposition and tau pathology are accompanied by microvascular compromise, capillary loss, and altered autoregulation, which are mirrored by thinning of the retinal nerve fiber layer (RNFL), reduced capillary density, and altered vessel geometry on retinal imaging. Vascular risk factors such as hypertension, diabetes, and dyslipidemia further exacerbate microvascular dysfunction. Mechanistically, retinal vascular changes are thought to reflect cerebral hypoxia, oxidative stress, endothelial dysfunction, and disrupted neurovascular coupling, all of which contribute to neurodegeneration and cognitive decline.

Risk Factors

Major risk factors for retinal vascular changes in the context of neurodegenerative disorders include advanced age, hypertension, diabetes mellitus, hyperlipidemia, smoking, and genetic predispositions (e.g., APOE ε4 allele). Systemic vascular disease, metabolic syndrome, and chronic inflammation are established contributors to both retinal and cerebral microvascular pathology. Several longitudinal studies have shown that individuals with a greater burden of cardiovascular risk factors exhibit more pronounced retinal vascular abnormalities and are at higher risk of developing cognitive impairment and dementia. The interplay between systemic risk factors and retinal vascular health highlights the importance of holistic patient assessment and risk modification in both ophthalmology and neurology practices.

Clinical Features

Retinal vascular biomarkers are typically asymptomatic but can be detected through specialized imaging techniques. Key features include narrowed arterioles, dilated venules, increased vessel tortuosity, microaneurysms, capillary dropout, and reduced perfusion density, which may precede or parallel cognitive and motor symptoms of neurodegenerative diseases. In Alzheimer’s disease, characteristic findings include thinning of the RNFL and ganglion cell–inner plexiform layer, as well as reduced parafoveal vessel density. In Parkinson’s disease, studies report microvascular alterations and decreased retinal capillary density, which may correlate with disease severity and duration. These features, though not diagnostic alone, provide critical adjunctive information complementing neurological assessment and neuroimaging.

Diagnosis

The diagnostic utility of retinal vascular biomarkers lies in their ability to non-invasively detect early microvascular and neurodegenerative changes. Techniques such as OCTA, scanning laser ophthalmoscopy, and digital fundus photography allow quantification of vessel caliber, perfusion density, foveal avascular zone (FAZ) area, and capillary non-perfusion. Automated image analysis and artificial intelligence (AI)-driven algorithms further enhance sensitivity and specificity by detecting subtle vascular changes and integrating multimodal data. Retinal imaging can be performed in outpatient settings, facilitating large-scale screening and longitudinal monitoring. However, standardization of imaging protocols, normative databases, and integration into clinical workflows remain ongoing challenges.

Treatment & Management

While retinal vascular biomarkers are primarily diagnostic and prognostic tools, their identification has important implications for patient management. Detection of retinal vascular abnormalities in at-risk individuals may prompt more aggressive control of vascular risk factors, early cognitive assessment, and referral for neurological evaluation. Current disease-modifying therapies for neurodegenerative disorders remain limited; however, emerging evidence suggests that improving vascular health through blood pressure control, glycemic management, lipid lowering, and lifestyle modification may slow progression of both retinal and cerebral pathology. Multidisciplinary care models integrating neurology, ophthalmology, and primary care are recommended to optimize outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in retinal imaging technology and analytical methods. Ultra-widefield imaging, adaptive optics, and AI-based pattern recognition are enhancing the detection and quantification of subtle retinal vascular changes. Several studies are exploring the role of retinal imaging as a surrogate endpoint in clinical trials of disease-modifying and neuroprotective therapies. Investigational therapies targeting vascular endothelial function, amyloid clearance, and neuroinflammation may impact retinal and cerebral microvasculature. Novel biomarkers, such as retinal amyloid imaging and quantitative capillary flow analysis, are under active investigation. These advances hold promise for more precise phenotyping, risk prediction, and monitoring of neurodegenerative disorders.

Guideline Recommendations

Major clinical guidelines, including those from the American Academy of Neurology and Alzheimer’s Association, increasingly recognize the value of retinal imaging as an adjunctive tool for risk stratification and early detection of neurodegenerative disease. While routine screening is not yet universally recommended, emerging consensus supports the integration of retinal vascular assessment in high-risk populations and research protocols. Guidelines emphasize the need for standardized imaging protocols, robust normative data, and interdisciplinary collaboration to facilitate translation of retinal biomarkers into routine clinical practice.

Conclusion

Retinal vascular biomarkers offer a unique, non-invasive approach to detecting and monitoring microvascular pathology in neurodegenerative disorders. Their clinical utility is supported by a growing body of evidence linking retinal vascular changes to cognitive impairment, disease progression, and systemic risk factors. Advances in imaging technology and analytical methods are accelerating the integration of retinal biomarkers into clinical practice and research. Continued interdisciplinary collaboration, standardization, and validation are essential to realize the full potential of retinal vascular biomarkers in improving outcomes for patients with neurodegenerative diseases.